88,824 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Thunderbird Partners LLP

Thunderbird Partners LLP acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 88,824 shares of the life sciences company's stock, valued at approximately $11,870,000. Illumina makes up approximately 19.2% of Thunderbird Partners LLP's holdings, making the stock its 3rd biggest holding. Thunderbird Partners LLP owned about 0.06% of Illumina at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Capital World Investors raised its holdings in Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares in the last quarter. Norges Bank bought a new stake in shares of Illumina in the 4th quarter worth $228,714,000. Bessemer Group Inc. lifted its holdings in shares of Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares during the period. WCM Investment Management LLC boosted its stake in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after buying an additional 867,673 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in Illumina by 245.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company's stock worth $158,011,000 after acquiring an additional 840,423 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 0.3 %

NASDAQ:ILMN traded down $0.26 during mid-day trading on Friday, reaching $77.35. The stock had a trading volume of 1,424,483 shares, compared to its average volume of 2,280,770. The stock has a market cap of $12.24 billion, a P/E ratio of -10.07, a PEG ratio of 1.60 and a beta of 1.38. The business's 50 day moving average is $82.50 and its 200 day moving average is $118.63. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler raised their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and decreased their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird cut their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, Citigroup decreased their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.